The insulin-like growth factor system as a treatment target in breast cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 11, 2002, Pages 86-95

  Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN RECEPTOR;

APOPTOSIS; BREAST CANCER; CELL PROLIFERATION; CELL PROTECTION; CONFERENCE PAPER; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0036312255     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70131-0     Document Type: Conference Paper

References (91)

1. Tamoxifen in the treatment of breast cancer
2. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
3. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations
4. Insulin-like growth factor II mRNA expression in human breast cancer
5. In situ analysis of IGF-II mRNA and protein in invasive breast carcinoma-evidence for paracrine functions
6. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study
7. Expression of IGF-I and IGF-II mRNA in breast tissue
8. A single receptor binds both insulin-like growth factor II and mannose-6-phosphate
9. Structure of the receptor for insulin-like growth factor II: The puzzle amplified
10. Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid
11. Structure and function of the mannose-6-phosphate/insulinlike growth factor-II receptors
12. Insulin-like growth factor II receptor as a multifunctional binding protein
13. Expression and characterization of a functional human insulin-like growth factor I receptor
14. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define hormonal specificity
15. Molecular and cellular aspects of the insulin-like growth factor I receptor
16. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism
17. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling
18. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor
19. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells
20. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation
21. The IRS-signaling system: A network of docking proteins that mediate insulin action
22. Insulin-like growth factor binding proteins: New proteins, new functions
23. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells
24. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells - Cell surface binding and growth inhibition
25. The insulin-like growth factor-binding protein superfamily
26. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid
27. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development
28. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model
29. Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression
30. Inability of overexpressed des(1-3)human insulin-like growth factor I (IGF-I) to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules
31. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis
32. The IGF-I receptor in cell growth, transformation and apoptosis
33. Insulin-like growth factor I receptor signaling in transformation by src oncogenes
34. Insulin-like growth factor-I receptor - Its role in cell proliferation, apoptosis, and tumorigenicity
35. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor
36. The role of the insulin-like growth factor I receptor in the transformation by simian virus 40 T antigen
37. Simian virus-40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-1 insulin-like growth factor receptor
38. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
39. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells
40. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase
41. Insulin-like growth factor I activates C-jun N-terminal kinase in MCF-7 breast cancer cells
42. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells
43. Enhancement of the insulin-like growth factor pathway by estrogen in human breast cancer cells
44. Estrogen receptor alpha rapidly activates the IGF-I receptor pathway
45. Insulin and IGF-I receptors signaling in protection from apoptosis
46. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-x(L) gene product
47. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - Proliferative and anti-apoptotic effects
48. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer
49. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
50. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
51. Insulin-like growth factor-I receptor overexpression mediates cellular radio resistance and local breast cancer recurrence after lumpectomy and radiation
52. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells
53. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer
54. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines
55. Serum insulin-like growth factor-I and breast cancer
56. Insulin like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast
57. Free insulin-like growth factor-I and breast cancer risk
58. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density
59. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis
60. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers
61. M6P/IGF2 receptor: A candidate breast tumor suppressor gene
62. IGF system components as prognostic markers in breast cancer
63. Interaction of the monoclonal antibodies alpha IR-1 and alpha IR-3 with insulin and somatomedin-C receptors
64. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
65. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor
66. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor - Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alphaIR-3)
67. Substrate competitive inhibitors of IGF-1 receptor kinase
68. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins
69. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression
70. EGF receptor in neoplasia and metastasis
71. Etanercept (Enbrel): Update on therapeutic use
72. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
73. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
74. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
75. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
76. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action
77. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells
78. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: Effects of affinity for IGF-I
79. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I
80. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line
81. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
82. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components
83. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice
84. Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice
85. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: Overview and case reports of three patients, including two now receiving gene therapy
86. Estrogen effects on insulin-like growth factor-I (IGF-I)-induced cell proliferation and IGF-I expression in native and allograft vessels
87. Insulin-like growth factor I and its binding proteins in the cardiovascular system
88. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
89. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
90. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
91. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas